Jon Blaskovich
Chief Tech/Sci/R&D Officer bei BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Profil
Herr Jon Blaskovich ist Direktor für Informationstechnologie bei Biohaven Pharmaceutical Holding Co. Ltd. Er erwarb seinen Bachelor-Abschluss am Rochester Institute of Technology.
Aktive Positionen von Jon Blaskovich
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Chief Tech/Sci/R&D Officer | - |
| BIOHAVEN LTD. | Chief Tech/Sci/R&D Officer | - |
Ehemalige bekannte Positionen von Jon Blaskovich
| Unternehmen | Position | Ende |
|---|---|---|
Epsilon Data Management LLC
 Epsilon Data Management LLC Advertising/Marketing ServicesCommercial Services Epsilon Data Management LLC provides marketing and data management services. It offers multi channel marketing, technologies and database solutions, strategic consulting, and account management services. The company was founded in 1969 and is headquartered in Irving, TX. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Jon Blaskovich
| Rochester Institute of Technology | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOHAVEN LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Epsilon Data Management LLC
Epsilon Data Management LLC Advertising/Marketing ServicesCommercial Services Epsilon Data Management LLC provides marketing and data management services. It offers multi channel marketing, technologies and database solutions, strategic consulting, and account management services. The company was founded in 1969 and is headquartered in Irving, TX. | Commercial Services |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
